Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world

AIDS Reviews

Volumn 14, Issue 1, 2012, Pages 17-27

  Frentz, Dineke ^a   Boucher, Charles A B ^a   Van De Vijver, David A M C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance mutations; HIV 1; Resistance prevalence; Transmitted drug resistance

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASIA; DRUG EFFICACY; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NONHUMAN; NORTH AMERICA; PACIFIC ISLANDS; REVIEW; SEROEPIDEMIOLOGY; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS TRANSMISSION;

AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; DRUG RESISTANCE, VIRAL; EUROPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LATIN AMERICA; NORTH AMERICA; PREVALENCE; TIME FACTORS;

EID: 84858988089     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (271)

1. Wittkop L, Gunthard H, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-71.
2. Wensing A, Boucher C. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003;5:140-55. (Pubitemid 37336631)
3. Geretti A. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32. (Pubitemid 46052123)
4. Van de Vijver D, Wensing A, Boucher C. The epidemiology of transmission of drug resistant HIV-1. HIV Sequence Compendium. 2007;2006/2007:17-36.
5. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11:575-9. (Pubitemid 44277422)
6. Lockman S, Shapiro R, Smeaton L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-47. (Pubitemid 46089674)
7. SPREAD Program. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22:625-35.
8. Grant R, Hecht F, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-8. (Pubitemid 34755278)
9. UNAIDS WHO. AIDS epidemic update, December 2009.
10. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2009. Stockholm: European Centre for Disease Prevention and Control, 2010.
11. UNAIDS. Report on the global HIV/AIDS epidemic, July 2002.
12. Mathers B, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733-45.
13. Vercauteren J, Wensing A, van de Vijver D, et al. Transmission of drugresistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200:1503-8.
14. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331:1368.
15. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-9.
16. Boucher C, O'Sullivan E, Mulder J, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992;165:105-10.
17. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-73.
18. Arrive E, Newell M, Ekouevi D, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36:1009-21. (Pubitemid 350018545)
19. Stringer J, McConnell M, Kiarie J, et al. Effectiveness of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multicountry, prospective cohort study. PLoS Med. 2010;7:e1000233.
20. World Health Organisation. Treat 3 million by 2005: Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2004.
21. Holmes C, Coggin W, Jamieson D, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA. 2010;304:313-20.
22. World Health Organisation. Treating 3 million by 2005: '3 by 5' Progress report, June 2005.
23. Agwale S, Zeh C, Paxinos E, et al. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses. 2006;22:22-6. (Pubitemid 43201513)
24. Dumans A, Soares M, Pieniazek D, et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother. 2002;46:3075-9.
25. Paraschiv S, Otelea D, Dinu M, Maxim D, Tinischi M. Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int J Infect Dis. 2007;11:123-8.
26. Eshleman S, Hudelson S, Gupta A, et al. Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses. 2005;21:93-7. (Pubitemid 40179805)
27. Wensing A, van de Vijver D, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-66. (Pubitemid 41266791)
28. Leaity S, Sherr L, Wells H, et al. Repeat HIV testing: high-risk behaviour or risk reduction strategy? AIDS. 2000;14:547-52. (Pubitemid 30209697)
29. Booth C, Garcia-Diaz A, Youle M, Johnson M, Phillips A, Geretti A. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother. 2007;59:517-24. (Pubitemid 47073459)
30. van Maarseveen N, Wensing A, de Jong D, et al. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis. 2007;195:399-409. (Pubitemid 46146118)
31. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14:125-30.
32. Shafer R, Rhee S, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21:215-23. (Pubitemid 46036930)
33. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 2008;49:196-204.
34. Metzner K, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS. 2005;19:1819-25. (Pubitemid 41546600)
35. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38:3919-25. (Pubitemid 32233182)
36. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29:165-8. (Pubitemid 34164888)
37. Toni T, Masquelier B, Bonard D, et al. Primary HIV-1 drug resistance in Abidjan (Cote d'Ivoire): a genotypic and phenotypic study. AIDS. 2002;16:488-91. (Pubitemid 34165384)
38. Fonjungo P, Mpoudi E, Torimiro J, et al. Human immunodeficiency virus type 1 group m protease in Cameroon: genetic diversity and protease inhibitor mutational features. J Clin Microbiol. 2002;40:837-45. (Pubitemid 34208632)
39. Pillay C, Bredell H, McIntyre J, Gray G, Morris L. HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses. 2002;18:605-10. (Pubitemid 34579540)
40. Toni T, Recordon-Pinson P, Minga A, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study. AIDS Res Hum Retroviruses. 2003;19:713-17. (Pubitemid 37047097)
41. Gordon M, De Oliveira T, Bishop K, et al. Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu- Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol. 2003;77:2587-99. (Pubitemid 36222783)
42. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses. 2003;19:151-60. (Pubitemid 36308053)
43. Hirsch M, Conway B, D'Aquila R, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998;279:1984-91.
44. Vergne L, Kane C, Laurent C, et al. Low rate of genotypic HIV-1 drugresistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS. 2003;17(Suppl 3):S31-8. (Pubitemid 36951667)
45. Adje-Toure C, Bile CE, Borget M, et al. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02-AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2003;34:111-13. (Pubitemid 37100120)
46. Konings F, Zhong P, Agwara M, et al. Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses. 2004;20:105-9. (Pubitemid 38147182)
47. Birk M, Sonnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS. 1998;12:2369-75. (Pubitemid 28558594)
48. Bessong P, Larry Obi C, Cilliers T, et al. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005;21:103-9. (Pubitemid 40179807)
49. Bussmann H, Novitsky V, Wester W, et al. HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother. 2005;16:103-15. (Pubitemid 41529730)
50. Shafer R. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247-77. (Pubitemid 34303765)
51. Bellocchi M, Forbici F, Palombi L, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol. 2005;76:452-8. (Pubitemid 40943252)
52. Petch L, Hoffman I, Jere C, et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses. 2005;21:799-805. (Pubitemid 41434185)
53. Maslin J, Rogier C, Caron M, Grandadam M, Koeck J, Nicand E. Short communication. Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa). Antivir Ther. 2005;10:855-9. (Pubitemid 41652980)
54. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med. 2005;13:51-7.
55. Koizumi Y, Ndembi N, Miyashita M, et al. Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr. 2006;43:15-22. (Pubitemid 44306482)
56. Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, Peeters M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol. 2006;36:43-9. (Pubitemid 44382730)
57. Vidal N, Mulanga C, Bazepeo S, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses. 2006;22:202-6. (Pubitemid 43277157)
58. Vessiere A, Nerrienet E, Kfutwah A, et al. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaounde, Cameroon. J Acquir Immune Defic Syndr. 2006;42:256-8. (Pubitemid 43884723)
59. Tebit D, Ganame J, Sathiandee K, Nagabila Y, Coulibaly B, Krausslich H. Diversity of HIV in rural Burkina Faso. J Acquir Immune Defic Syndr. 2006;43:144-52. (Pubitemid 44454807)
60. Ojesina A, Sankale J, Odaibo G, et al. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses. 2006;22:770-9. (Pubitemid 44735004)
61. Nadembega W, Giannella S, Simpore J, et al. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol. 2006;78:1385-91. (Pubitemid 44533865)
62. Razafindratsimandresy R, Rajaonatahina D, Soares J, Rousset D, Reynes JM. High HIV type 1 subtype diversity and few drug resistance mutations among seropositive people detected during the 2005 second generation HIV surveillance in Madagascar. AIDS Res Hum Retroviruses. 2006;22:595-7.
63. Marechal V, Jauvin V, Selekon B, et al. Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study. AIDS Res Hum Retroviruses. 2006;22:1036-44. (Pubitemid 46100690)
64. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med. 2005;13:125-31.
65. Bessong P, Mphahlele J, Choge I, et al. Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses. 2006;22:1306-12. (Pubitemid 46095250)
66. Parreira R, Piedade J, Domingues A, et al. Genetic characterization of human immunodeficiency virus type 1 from Beira, Mozambique. Microbes Infect. 2006;8:2442-51. (Pubitemid 44499038)
67. Vidal N, Niyongabo T, Nduwimana J, et al. HIV Type 1 Diversity and Antiretroviral Drug Resistance Mutations in Burundi. AIDS Res Hum Retroviruses. 2007;23:175-80. (Pubitemid 46214187)
68. Derache A, Traore O, Koita V, et al. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther. 2007;12:123-9. (Pubitemid 46340435)
69. Toni T, Masquelier B, Minga A, et al. HIV-1 Antiretroviral Drug Resistance in Recently Infected Patients in Abidjan, Cote d'Ivoire: A 4-Year Survey, 2002-2006. AIDS Res Hum Retroviruses. 2007;23:1155-60. (Pubitemid 47571940)
70. Galluzzo C, Germinario E, Bassani L, et al. Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda. AIDS Res Hum Retroviruses. 2007;23:1449-51.
71. Ndembi N, Abraha A, Pilch H, et al. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B J Clin Microbiol. 2008;46:177-84.
72. Deho L, Walwema R, Cappelletti A, et al. Subtype assignment and phylogenetic analysis of HIV type 1 strains in patients from Swaziland. AIDS Res Hum Retroviruses. 2008;24:323-5. (Pubitemid 351282114)
73. Ndembi N, Lyagoba F, Nanteza B, et al. Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses. 2008;24:889-95. (Pubitemid 351871676)
74. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119-25.
75. Somi G, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther. 2008;13(Suppl 2):77-82. (Pubitemid 352019092)
76. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008;13(Suppl 2):101-7. (Pubitemid 352019096)
77. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther. 2008;13(Suppl 2):83-7. (Pubitemid 352019093)
78. Abegaz W, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther. 2008;13(Suppl 2):89-94. (Pubitemid 352019094)
79. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther. 2008;13(Suppl 2):95-100. (Pubitemid 352019095)
80. Bartolo I, Casanovas J, Bastos R, et al. HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. J Acquir Immune Defic Syndr. 2009;51:323-31.
81. Shafer R, Rhee S, Bennett D. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008;13(Suppl 2):59-68. (Pubitemid 352019090)
82. Bartolo I, Rocha C, Bartolomeu J, et al. Antiretroviral drug resistance surveillance among treatment-naive HIV-1-infected individuals in Angola: evidence for low level of transmitted drug resistance. Antimicrob Agents Chemother. 2009;53:3156-8.
83. Eshleman S, Laeyendecker O, Parkin N, et al. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS. 2009;27:845-52.
84. Tebit D, Sangare L, Tiba F, et al. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso. J Med Virol. 2009;81:1691-701.
85. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16:138-45.
86. Aghokeng A, Vergne L, Mpoudi-Ngole E, et al. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther. 2009;14:401-11.
87. Brodine S, Shaffer R, Starkey M, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med. 1999;131:502-6. (Pubitemid 29482393)
88. Alexander C, Dong W, Schechter M, et al. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS. 1999;13:981-5. (Pubitemid 29240194)
89. Wegner S, Brodine S, Mascola J, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS. 2000;14:1009-15. (Pubitemid 30336062)
90. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis. 2000;182:330-3. (Pubitemid 30497825)
91. Alexander C, Dong W, Chan K, et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS. 2001;15:601-7. (Pubitemid 32281355)
92. Verbiest W, Brown S, Cohen C, et al. Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. AIDS. 2001;15:647-50. (Pubitemid 32281363)
93. Nannini E, Han X, O'Brien W, Arduino R. Genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in Houston, Texas. J Acquir Immune Defic Syndr. 2002;29:317-19. (Pubitemid 34208544)
94. Ristig M, Arens M, Kennedy M, Powderly W, Tebas P. Increasing prevalence of resistance mutations in antiretroviral-naive individuals with established HIV-1 infection from 1996-2001 in St. Louis. HIV Clin Trials. 2002;3:155-60. (Pubitemid 34520993)
95. Hirsch M, Brun-Vezinet F, D'Aquila R, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-26. (Pubitemid 30257541)
96. D'Aquila R, Schapiro J, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2002;10:21-5.
97. Little S, Holte S, Routy J, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94. (Pubitemid 34851830)
98. Sullivan P, Buskin S, Turner J, et al. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities. Int J STD AIDS. 2002;13:554-8. (Pubitemid 34816241)
99. Stone D, Corcoran C, Wurcel A, et al. Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. Clin Infect Dis. 2002;35:883-6.
100. Hanna G, D'Aquila R. Antiretroviral drug resistance in HIV-1. Curr Infect Dis Rep. 1999;1:289-97.
101. Juethner S, Williamson C, Ristig M, Tebas P, Seyfried W, Aberg JA. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr. 2003;32:153-6. (Pubitemid 36222716)
102. Hanna G, Balaguera H, Freedberg K, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis. 2003;188:986-91. (Pubitemid 37268248)
103. Weinstock H, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-80. (Pubitemid 38757188)
104. Holodniy M, Charlebois E, Bangsberg D, Zolopa A, Schulte M, Moss A. Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study. Int J STD AIDS. 2004;15:543-51. (Pubitemid 39120239)
105. Turner D, Brenner B, Routy J, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37:1627-31. (Pubitemid 39658205)
106. Johnson V, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:215-21.
107. Novak R, Chen L, MacArthur R, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40:468-74. (Pubitemid 40216518)
108. Hirsch M, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-28. (Pubitemid 36836653)
109. Welles S, Bauer G, Larussa P, Colgrove R, Pitt J. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and -naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr. 2007;44:329-35. (Pubitemid 46328351)
110. Jayaraman G, Archibald C, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr. 2006;42:86-90. (Pubitemid 43947951)
111. D'Aquila R, Schapiro J, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:92-6.
112. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006;41:439-46.
113. Grubb J, Singhatiraj E, Mondy K, Powderly W, Overton E. Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. AIDS. 2006;20:2115-16. (Pubitemid 44611065)
114. Truong H, Grant R, McFarland W, et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS. 2006;20:2193-7. (Pubitemid 44684710)
115. Viani R, Peralta L, Aldrovandi G, et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis. 2006;194:1505-9. (Pubitemid 44851891)
116. Ross L, Lim M, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007;8:1-8. (Pubitemid 46542904)
117. Smith D, Moini N, Pesano R, et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis. 2007;44:456-8. (Pubitemid 46147633)
118. Eshleman S, Husnik M, Hudelson S, et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS. 2007;21:1165-74. (Pubitemid 46763287)
119. Parker M, Gordon D, Reilly A, et al. Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naive, HIV-infected individuals in New York State. AIDS Patient Care STDS. 2007;21:644-52. (Pubitemid 47525387)
120. Brennan C, Stramer S, Holzmayer V, et al. Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion. 2009;49:125-33.
121. Gorbach P, Drumright L, Javanbakht M, et al. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr. 2008;47:639-43. (Pubitemid 351442022)
122. Huang H, Daar E, Sax P, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection. HIV Med. 2008;9:285-93. (Pubitemid 351517275)
123. Madsen T, Lohse N, Jensen E, et al. Short communication: high prevalence of drug-resistant human immunodeficiency virus type 1 in treatmentnaive patients in Greenland. AIDS Res Hum Retroviruses. 2008;24:1073-7.
124. Brenner B, Roger M, Moisi D, et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS. 2008; 22:2509-15.
125. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16:62-8.
126. Rahim S, Fredrick L, da Silva B, Bernstein B, King MS. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naive subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials. 2009;10:94-103.
127. James C, Moffett L, Szabo S. Prevalence of antiretroviral drug resistance in antiretroviral-naive individuals. J Int Assoc Physicians AIDS Care (Chic). 2009;8:193-5.
128. Hirsch M, Gunthard H, Schapiro J, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-85. (Pubitemid 351920631)
129. Hurt C, McCoy S, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther. 2009;14:673-8.
130. Tanuri A, Vicente A, Otsuki K, et al. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob Agents Chemother. 1999;43:253-8. (Pubitemid 29079154)
131. Cesaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabie A. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquir Immune Defic Syndr. 1999;22:401-5. (Pubitemid 30030433)
132. Ruibal-Brunet I, Cuevas M, Diaz-Torres H, et al. Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba. Rev Panam Salud Publica. 2001;10:174-80. (Pubitemid 32979561)
133. Kijak G, Pampuro S, Avila M, et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther. 2001;6:71-7. (Pubitemid 33704484)
134. Hammond J, Larder B, Schinazi R, Mellors J. Mutations in retroviral genes associated with drug resistance. In: Korber B, Foley B, Kuiken C, et al. (eds). A compilation and analysis of nucleic acid and amino acid sequences. Vol. III-207-49. Los Alamos National Laboratory: Human Retroviruses and AIDS, 1997.
135. Delgado E, Leon-Ponte M, Villahermosa M, et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS Res Hum Retroviruses. 2001;17:753-8. (Pubitemid 32692413)
136. Dumans A, Soares M, Pieniazek D, et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother. 2002;46:3075-9.
137. Brindeiro R, Diaz R, Sabino E, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS. 2003;17:1063-9. (Pubitemid 36549719)
138. Pires I, Soares M, Speranza F, et al. Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J Clin Microbiol. 2004;42:426-30. (Pubitemid 38082763)
139. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al. Drugresistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med. 2005;6:403-9. (Pubitemid 41723308)
140. Eyer-Silva W, Morgado M. A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality. Mem Inst Oswaldo Cruz. 2005;100:869-73. (Pubitemid 43213814)
141. Kantor R, Machekano R, Gonzales M, Dupnik K, Schapiro J, Shafer R. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 2001;29:296-9. (Pubitemid 32054474)
142. Dieudonne M, Garzaro D, Torres J, et al. High prevalence of secondary resistance mutations in Venezuelan HIV-1 isolates. Invest Clin. 2006;47:27-34.
143. Rodrigues R, Scherer L, Oliveira C, et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res. 2006;116:201-7. (Pubitemid 43221733)
144. Barreto C, Nishyia A, Araujo L, Ferreira J, Busch M, Sabino E. Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr. 2006;41:338-41.
145. Lama J, Sanchez J, Suarez L, et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr. 2006;42:501-5. (Pubitemid 44050901)
146. Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr. 2006;42:506-10. (Pubitemid 44050902)
147. de Medeiros L, Lacerda H, Cavalcanti A, de Albuquerque M. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2006;101:845-9. (Pubitemid 46131332)
148. Maia Teixeira S, Bastos F, Hacker M, Guimaraes M, Morgado M. Trends in drug resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. J Med Virol. 2006;78:764-9.
149. Valle-Bahena O, Ramos-Jimenez J, Ortiz-Lopez R, et al. Frequency of protease and reverse transcriptase drug resistance mutations in naive HIV-infected patients. Arch Med Res. 2006;37:1022-7. (Pubitemid 44540239)
150. Sa-Ferreira J, Brindeiro P, Chequer-Fernandez S, Tanuri A, Morgado MG. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naive Brazilian blood donors. Transfusion. 2007;47:97-102. (Pubitemid 46006315)
151. Bouchard M, Masquelier B, Moreno M, et al. HIV type 1 drug resistance among naive patients from Venezuela. AIDS Res Hum Retroviruses. 2007;23:482-5. (Pubitemid 46608570)
152. Perez L, Alvarez L, Carmona R, et al. Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS Res Hum Retroviruses. 2007;23:407-14. (Pubitemid 46608561)
153. Rios M, Delgado E, Perez-Alvarez L, et al. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med Virol. 2007;79:647-56. (Pubitemid 46709357)
154. Gonsalez CR, Alcalde R, Nishiya A, et al. Drug resistance among chronic HIV-1- infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus Res. 2007;129:87-90. (Pubitemid 47595356)
155. Rangel H, Garzaro D, Torres J, et al. Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Mem Inst Oswaldo Cruz. 2009;104:522-5.
156. Sprinz E, Netto E, Patelli M, et al. Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Retroviruses. 2009;25:861-7.
157. Cardoso L, Queiroz B, Stefani M. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naive patients from Central West Brazil. J Clin Virol. 2009;46:134-9.
158. Fontaine E, Lambert C, Servais J, et al. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatmentnaive patients. J Hum Virol. 1998;1:451-6. (Pubitemid 128543590)
159. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drugselected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;41:284-91. (Pubitemid 27111020)
160. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviralexperienced HIV-infected patients in Spain. AIDS. 1998;12:1015-20. (Pubitemid 28276968)
161. Tambussi G, Boeri E, Carrera P, Gianotti N, Lazzarin A. Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naive HIV-1 positive subjects during the period 1984-1997. J Biol Regul Homeost Agents. 1998;12:32-4.
162. Schnatz I, Larder B, Mellors J. Mutations in retroviral genes associated with drug resistance. Int Antiviral News. Vol. special issue, 1997.
163. Loveday C, Devereux H, Huckett L, Johnson M. High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population. AIDS. 1999;13:627-8. (Pubitemid 29286734)
164. Magiorkinis E, Paraskevis D, Lazanas M, Kiosses V, Gargalianos P, Hatzakis A. Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients. AIDS. 1999;13:1276-8. (Pubitemid 29361101)
165. Yerly S, Kaiser L, Race E, Bru J, Clavel F, Perrin L. Transmission of antiretroviral drug-resistant HIV-1 variants. Lancet. 1999;354:729-33. (Pubitemid 29407396)
166. Schinazi R, Larder B, Mellors J. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News. 1997;5:129-42.
167. Balotta C, Berlusconi A, Pan A, et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther. 2000;5:7-14. (Pubitemid 30261199)
168. Cenci A, Bertoli A, Tambussi G, et al. Viral dynamics and mutations in the pol gene during primary HIV-1 infection. J Biol Regul Homeost Agents. 2000;14:7-10. (Pubitemid 32288557)
169. Barber A, Hizi A, Maizel JV, Hughes S. HIV-1 reverse transcriptase: structure predictions for the polymerase domain. AIDS Res Hum Retroviruses. 1990;6:1061-72. (Pubitemid 20352117)
170. Romano L, Venturi G, Ferruzzi R, et al. Detection of genotypically drugresistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. AIDS. 2000;14:2204-6.
171. Zazzi M, Riccio M, Venturi G, et al. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Mol Biotechnol. 1998;10:1-8. (Pubitemid 28435829)
172. Puig T, Perez-Olmeda M, Rubio A, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS. 2000;14:727-32. (Pubitemid 30229352)
173. Pillay D, Cane P, Shirley J, Porter K. Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS. 2000;14:906-8. (Pubitemid 30303476)
174. Shafer R, Stevenson D, Chan B. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Nucleic Acids Res. 1999;27:348-52. (Pubitemid 29209482)
175. Perez-Alvarez L, Villahermosa M, Cuevas M, et al. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies. J Hum Virol. 2000;3:150-6. (Pubitemid 30471147)
176. Van Vaerenbergh K, Debaisieux L, De Cabooter N, et al. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antivir Ther. 2001;6:63-70. (Pubitemid 33704483)
177. Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol. 2000;61:181-6. (Pubitemid 30257241)
178. Perez-Olmeda M, Del Romero J, Rubio A, et al. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. J Med Virol. 2001;63:85-7. (Pubitemid 32142263)
179. de Ronde A, van Dooren M, van der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol. 2001;75:595-602.
180. Duwe S, Brunn M, Altmann D, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr. 2001;26: 266-73. (Pubitemid 32246557)
181. Re M, Monari P, Borderi M, et al. Presence of genotypic resistance to antiretroviral drugs in a cohort of therapy-naive HIV-1-infected Italian patients. J Acquir Immune Defic Syndr. 2001;27:315-16. (Pubitemid 32661976)
182. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ. 2001;322:1087-8.
183. Geretti A, Smith M, Osner N, et al. Prevalence of antiretroviral resistance in a South London cohort of treatment-naive HIV-1-infected patients. AIDS. 2001;15:1082-4. (Pubitemid 32476687)
184. Descamps D, Calvez V, Izopet J, et al. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. AIDS. 2001;15:1777-82. (Pubitemid 32939237)
185. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS. 2001;15:1894-6. (Pubitemid 32939257)
186. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001;15: 2287-92. (Pubitemid 34059836)
187. Schinazi R, Larder BA, Mellors J. Resistance table: mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News. 2000;8:65-91. (Pubitemid 30398430)
188. Fidler S, Frater J, Clarke J, Weber J. HIV-1 drug resistance in primary infections in the UK. BMJ. 2001;323:632-3. (Pubitemid 32846141)
189. Clevenbergh P, Cua E, Dam E, et al. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clin Trials. 2002;3:36-44. (Pubitemid 34183094)
190. Violin M, Forbici F, Cozzi-Lepri A, et al. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. J Biol Regul Homeost Agents. 2002;16:37-43. (Pubitemid 34495587)
191. Magiorkinis E, Paraskevis D, Magiorkinis G, et al. Mutations associated with genotypic resistance to antiretroviral therapy in treatment naive HIV-1 infected patients in Greece. Virus Res. 2002;85:109-15. (Pubitemid 34310529)
192. Hertogs K, Bloor S, De Vroey V, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000;44:568-73. (Pubitemid 30117942)
193. Easterbrook P, Hertogs K, Waters A, Wills B, Gazzard B, Larder B. Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991. J Infect. 2002;44:88-91. (Pubitemid 34785346)
194. Eiros J, Labayru C, Hernandez B, Ortega M, Bachiller P, Ortiz de Lejarazu R. Prevalence of genotypic resistance in untreated HIV patients in Spain. Eur J Clin Microbiol Infect Dis. 2002;21:310-13. (Pubitemid 34507879)
195. Harzic M, Pellegrin I, Deveau C, et al. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS. 2002;16:793-6. (Pubitemid 34274472)
196. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH 2000. Paris: Médicine - Sciences, Flammarion 2000:17-28.
197. de Mendoza C, del Romero J, Rodriguez C, Corral A, Soriano V. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS. 2002;16:1830-2.
198. Antiretroviral Resistance Mutations (revised April 2001). HIV Clin Trials. 2001;2:346-55.
199. Geretti A, Smith M, Watson C, et al. Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1. AIDS. 2002;16:2358-60. (Pubitemid 35449032)
200. Gallego O, Corral A, De Mendoza C, Gonzalez-Lahoz J, Soriano V. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. Med Sci Monit. 2003;9:CR217-21. (Pubitemid 36850710)
201. Maljkovic I, Wilbe K, Solver E, Alaeus A, Leitner T. Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drugnaive patients infected with subtypes A, B, C, D, G, U, and CRF01-AE. AIDS Res Hum Retroviruses. 2003;19:989-97. (Pubitemid 37476027)
202. Chaix M, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17:2635-43. (Pubitemid 38402342)
203. Jorgensen L, Christensen M, Gerstoft J, et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis. 2003;35:800-7. (Pubitemid 38028914)
204. Re M, Monari P, Bon I, Borderi M, Chiodo F. Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection. Int J Antimicrob Agents. 2004;23:164-8. (Pubitemid 38175398)
205. Perez-Alvarez L, Carmona R, Munoz M, et al. High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance. Antivir Ther. 2003;8:355-60. (Pubitemid 37101640)
206. Violin M, Velleca R, Cozzi-Lepri A, et al. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr. 2004;36:761-4. (Pubitemid 38685973)
207. Derdelinckx I, Van Laethem K, Maes B, et al. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr. 2004;37:1664-6. (Pubitemid 39658210)
208. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drugresistant variants. Antivir Ther. 2004;9:375-84. (Pubitemid 38878753)
209. Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS. 2004;18:1571-7. (Pubitemid 39037481)
210. Oette M, Kaiser R, Daumer M, et al. Primary drug-resistance in HIVpositive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res. 2004;9:273-8.
211. Roudinskii N, Sukhanova A, Kazennova E, et al. Diversity of human immunodeficiency virus type 1 subtype A and CRF03-AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations. J Virol. 2004;78:11276-87. (Pubitemid 39299667)
212. Eiros J, Blanco R, Labayru C, et al. Prevalence of genotypic resistance in untreated HIV-infected patients. Rev Esp Quimioter. 2004;17:250-6. (Pubitemid 39577258)
213. Filippini P, Liguori G, Scolastico C, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviralnaive HIV patients in Campania, Italy. J Chemother. 2004;16:534-9.
214. Clarke J, Kaye S, Babiker A, Hooker M, Tedder R, Weber J. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. J Virol Methods. 2000;88:117-24.
215. Grossman Z, Lorber M, Maayan S, et al. Drug-resistant HIV infection among drug-naive patients in Israel. Clin Infect Dis. 2005;40:294-302. (Pubitemid 40110677)
216. Vazquez de Parga E, Rakhmanova A, Perez-Alvarez L, et al. Analysis of drug resistance-associated mutations in treatment-naive individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol. 2005;77:337-44. (Pubitemid 41395863)
217. Paraskevis D, Magiorkinis E, Katsoulidou A, et al. Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res. 2005;112:115-22. (Pubitemid 40966783)
218. Johnson V, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004;12:119-24.
219. Descamps D, Chaix M, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr. 2005;38:545-52. (Pubitemid 40524476)
220. de Mendoza C, Rodriguez C, Colomina J, et al. Resistance to non-nucleoside reverse transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis. 2005;41:1350-4. (Pubitemid 41532683)
221. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005;40:505-11. (Pubitemid 41669152)
222. Corvasce S, Violin M, Romano L, et al. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther. 2006;11:329-34. (Pubitemid 43823551)
223. Oette M, Kaiser R, Daumer M, et al. Primary HIV drug resistance and efficacy of firstline antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr. 2006;41:573-81.
224. Zarandia M, Tsertsvadze T, Carr J, Nadai Y, Sanchez J, Nelson A. HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia. AIDS Res Hum Retroviruses. 2006;22:470-6. (Pubitemid 43787774)
225. Fox J, Dustan S, McClure M, Weber J, Fidler S. Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med. 2006;7:477-83. (Pubitemid 44269816)
226. Lindstrom A, Ohlis A, Huigen M, et al. HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther. 2006;11: 1031-9. (Pubitemid 44955179)
227. Garcia-Guerrero J, Saiz de la HP, Portilla J, Marco A, Sanchez-Paya J, Moreno S. Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates. Eur J Clin Microbiol Infect Dis. 2006;25:695-701. (Pubitemid 44806777)
228. Babic D, Zelnikar M, Seme K, et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res. 2006;118:156-63.
229. Palma A, Araujo F, Duque V, Borges F, Paixao M, Camacho R. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol. 2007;7:391-8. (Pubitemid 46667770)
230. Bon I, Gibellini D, Borderi M, et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol. 2007;38:313-20. (Pubitemid 46413996)
231. UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS. 2007;21:1035-9.
232. Poggensee G, Kucherer C, Werning J, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med. 2007;8:511-19. (Pubitemid 47616830)
233. Yerly S, von WV, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS. 2007;21:2223-9.
234. Sagir A, Oette M, Kaiser R, et al. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother. 2007;60:843-8. (Pubitemid 47434265)
235. Vercauteren J, Derdelinckx I, Sasse A, et al. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses. 2008;24:355-62. (Pubitemid 351457751)
236. Bannister W, Cozzi-Lepri A, Clotet B, et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr. 2008;48:324-33.
237. Payne B, Nsutebu E, Hunter E, et al. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother. 2008;62:464-8.
238. Street E, Armstrong N, Monteiro E, Hale A. An audit of baseline HIV-1 genotypic resistance testing in a UK provincial city. Int J STD AIDS. 2008;19:416-17.
239. Kousiappa I, van de Vijver D, Demetriades I, Kostrikis L. Genetic analysis of HIV type 1 strains from newly infected untreated patients in Cyprus: high genetic diversity and low prevalence of drug resistance. AIDS Res Hum Retroviruses. 2009;25:23-35.
240. Shafer R. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51-8. (Pubitemid 44420873)
241. Cuevas M, Munoz-Nieto M, Thomson M, et al. HIV-1 transmission cluster with T215D revertant mutation among newly diagnosed patients from the Basque Country, Spain. J Acquir Immune Defic Syndr. 2009;51:99-103.
242. Avi R, Huik K, Sadam M, et al. Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06-cpx in treatment-naive patients in Estonia. J Med Virol. 2009;81:953-8.
243. Yerly S, Junier T, Gayet-Ageron A, et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS. 2009;23:1415-23.
244. Alteri C, Svicher V, Gori C, et al. Characterization of the patterns of drug resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs. BMC Infect Dis. 2009;9:111.
245. Bracciale L, Colafigli M, Zazzi M, et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 2009;64:607-15.
246. Bennett D, Camacho R, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.
247. Rumyantseva O, Olkhovskiy I, Malysheva M, et al. Epidemiological networks and drug resistance of HIV type 1 in Krasnoyarsk Region, Russia. AIDS Res Hum Retroviruses 2009;25:931-6.
248. Sugiura W, Matsuda M, Abumi H, et al. Prevalence of drug resistance-related mutations among HIV-1 in Japan. Jpn J Infect Dis. 1999;52:21-2. (Pubitemid 29414618)
249. Jennifer H, Brendan A, Raymond F, John W. Mutations in retroviral genes associated with drug resistance. Hum Retrovir AIDS. 1997;III:207-49.
250. Auswinporn S, Jenwitheesuk E, Panburana P, Sirinavin S, Vibhagool A, Chantratita W. Prevalence of HIV-1 drug resistance in antiretroviral-naive pregnant Thai women. Southeast Asian J Trop Med Public Health. 2002;33:818-21.
251. Park S, Kim H, Choi Y, Kim N, Oh M, Choe K. Genotypic resistance of antiretroviral drugs among drug-naive HIV type 1 patients with the background of long-term access-easy zidovudine therapy. AIDS Res Hum Retroviruses. 2003;19:1039-43. (Pubitemid 37476033)
252. Lan N, Recordon-Pinson P, Hung P, et al. HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01-AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses. 2003;19:925-8. (Pubitemid 37338920)
253. Ibe S, Hotta N, Takeo U, et al. Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol Immunol. 2003;47:499-505. (Pubitemid 36898678)
254. Deshpande A, Recordon-Pinson P, Deshmukh R, et al. Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses. 2004;20:1032-5. (Pubitemid 39369712)
255. Ly N, Recordon-Pinson P, Phoung V, et al. Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs. AIDS Res Hum Retroviruses. 2005;21:971-6. (Pubitemid 41785786)
256. Gatanaga H, Ibe S, Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res. 2007;75:75-82. (Pubitemid 46610525)
257. Tee K, Kamarulzaman A, Ng K. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses. 2006;22:121-4. (Pubitemid 43277146)
258. Yam W, Chen J, Wong K, et al. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01-AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol. 2006;35:454-7. (Pubitemid 43324845)
259. Jiang S, Xing H, Si X, Wang Y, Shao Y. Polymorphism of the protease and reverse transcriptase and drug resistance mutation patterns of HIV-1 subtype B prevailing in China. J Acquir Immune Defic Syndr. 2006;42:512-14. (Pubitemid 44050904)
260. Han X, Zhang M, Dai D, et al. genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: Baseline prevalence and subtype-specific difference. AIDS Res Hum Retroviruses. 2007;23:357-64. (Pubitemid 46608555)
261. Zhang X, Li S, Li X, et al. Characterization of HIV-1 subtypes and viral antiretroviral drug resistance in men who have sex with men in Beijing, China. AIDS. 2007;21(Suppl 8):S59-65.
262. Kojima Y, Kawahata T, Mori H, Oishi I, Otake T. Recent diversity of human immunodeficiency virus type 1 in individuals who visited sexually transmitted infection related clinics in Osaka, Japan. J Infect Chemother. 2008;14:51-5. (Pubitemid 351311443)
263. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, et al. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med. 2008;9:322-5. (Pubitemid 351522665)
264. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, et al. Genotypic
265. Sirivichayakul S, Phanuphak P, Pankam T, O-Charoen R, Sutherland D, Ruxrungtham K. HIV drug resistance transmission threshold survey in Bangkok, Thailand. Antivir Ther. 2008;13(Suppl 2):109-13. (Pubitemid 352019097)
266. Nguyen H, Duc N, Shrivastava R, et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther. 2008;13(Suppl 2):115-21. (Pubitemid 352019098)
267. Janin N, Sopheak N, Regis MP, et al. Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia. AIDS Res Hum Retroviruses. 2009;25:543-5.
268. Lee C, Sun Y, Barkham T, Leo Y. Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naive seroconverters in Singapore. HIV Med. 2009;10:370-7.
269. Yu G, Li Y, Li J, et al. Genetic diversity and drug resistance of HIV type 1 circulating recombinant Form-BC among drug users in Guangdong Province. AIDS Res Hum Retroviruses. 2009;25:869-75.
270. Iqbal H, Solomon S, Madhavan V, Solomon S, Balakrishnan P. Primary HIV-1 Drug Resistance and Polymorphic Patterns Among Injecting Drug Users (IDUs) in Chennai, Southern India. J Int Assoc Physicians AIDS Care (Chic). 2009;8:323-7.
271. Ammaranond P, Cunningham P, Oelrichs R, et al. No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001. AIDS. 2003;17:264-7. (Pubitemid 36183056)